Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Jun;29(6):1053–1058. doi: 10.1128/aac.29.6.1053

Characterization of a varicella-zoster virus variant with altered thymidine kinase activity.

S Shigeta, S Mori, T Yokota, K Konno, E De Clercq
PMCID: PMC180499  PMID: 3015014

Abstract

A varicella-zoster virus (VZV) strain resistant to 5-iodo-2'-deoxyuridine (IdUrd) and 5-bromo-2'-deoxyuridine (BrdUrd) but sensitive to (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdUrd) and (E)-5-(2-iodovinyl)-2'-deoxyuridine (IVdUrd) was isolated. The 2'-deoxythymidine (dThd) kinase of this mutant (Ito) strain was characterized; it was much less efficient in phosphorylating dThd, 2'-deoxycytidine, and BrdUrd than were the dThd kinases from wild-type (CaQu, Kobayashi) VZV strains. The Ito dThd kinase had a markedly decreased affinity for dThd, 2'-deoxycytidine, and BrdUrd but only a slightly decreased affinity for IVdUrd than had the wild-type VZV dThd kinase. BrdUrd was incorporated to a much lesser extent in VZV (Ito strain)-infected cells than wild-type VZV-infected cells, but IVdUrd was incorporated in Ito VZV-infected cells as efficiently as in wild-type VZV-infected cells. While resistant to IdUrd and BrdUrd, the Ito strain was susceptible to inhibitors of de novo thymidylate biosynthesis such as aminopterin.

Full text

PDF
1053

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Coen D. M., Furman P. A., Gelep P. T., Schaffer P. A. Mutations in the herpes simplex virus DNA polymerase gene can confer resistance to 9-beta-D-arabinofuranosyladenine. J Virol. 1982 Mar;41(3):909–918. doi: 10.1128/jvi.41.3.909-918.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Coen D. M., Schaffer P. A. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2265–2269. doi: 10.1073/pnas.77.4.2265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. DUBBS D. R., KIT S. MUTANT STRAINS OF HERPES SIMPLEX DEFICIENT IN THYMIDINE KINASE-INDUCING ACTIVITY. Virology. 1964 Apr;22:493–502. doi: 10.1016/0042-6822(64)90070-4. [DOI] [PubMed] [Google Scholar]
  4. Darby G., Field H. J., Salisbury S. A. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. Nature. 1981 Jan 1;289(5793):81–83. doi: 10.1038/289081a0. [DOI] [PubMed] [Google Scholar]
  5. De Clercq E., Descamps J., Ogata M., Shigeta S. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds. Antimicrob Agents Chemother. 1982 Jan;21(1):33–38. doi: 10.1128/aac.21.1.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dobersen M. J., Jerkofsky M., Greer S. Enzymatic basis for the selective inhibition of varicella-zoster virus by 5-halogenated analogues of deoxycytidine. J Virol. 1976 Nov;20(2):478–486. doi: 10.1128/jvi.20.2.478-486.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Field H. J., Wildy P. The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J Hyg (Lond) 1978 Oct;81(2):267–277. doi: 10.1017/s0022172400025109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Field H., McMillan A., Darby G. The sensitivity of acyclovir-resistant mutants of herpes simplex virus to other antiviral drugs. J Infect Dis. 1981 Feb;143(2):281–285. doi: 10.1093/infdis/143.2.281. [DOI] [PubMed] [Google Scholar]
  9. Fyfe J. A. Differential phosphorylation of (E)-5-(2-bromovinyl)-2'-deoxyuridine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus. Mol Pharmacol. 1982 Mar;21(2):432–437. [PubMed] [Google Scholar]
  10. Gershon A. A., Steinberg S. P., Gelb L., Galasso G., Borkowsky W., LaRussa P., Farrara A. Live attenuated varicella vaccine. Efficacy for children with leukemia in remission. JAMA. 1984 Jul 20;252(3):355–362. doi: 10.1001/jama.252.3.355. [DOI] [PubMed] [Google Scholar]
  11. Hackstadt T., Mallavia L. P. Deoxypyrimidine nucleoside metabolism in varicella-zoster virus-infected cells. J Virol. 1978 Feb;25(2):510–517. doi: 10.1128/jvi.25.2.510-517.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Larder B. A., Darby G. Properties of a novel thymidine kinase induced by an acyclovir-resistant herpes simplex virus type 1 mutant. J Virol. 1982 May;42(2):649–658. doi: 10.1128/jvi.42.2.649-658.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Schnipper L. E., Crumpacker C. S. Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2270–2273. doi: 10.1073/pnas.77.4.2270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Shigeta S., Yokota T., Iwabuchi T., Baba M., Konno K., Ogata M., De Clercq E. Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus. J Infect Dis. 1983 Mar;147(3):576–584. doi: 10.1093/infdis/147.3.576. [DOI] [PubMed] [Google Scholar]
  15. Takahashi M., Otsuka T., Okuno Y., Asano Y., Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet. 1974 Nov 30;2(7892):1288–1290. doi: 10.1016/s0140-6736(74)90144-5. [DOI] [PubMed] [Google Scholar]
  16. Tenser R. B. Intracerebral inoculation of newborn and adult mice with thymidine kinase-deficient mutants of herpes simplex virus type 1. J Infect Dis. 1983 May;147(5):956–956. doi: 10.1093/infdis/147.5.956. [DOI] [PubMed] [Google Scholar]
  17. Yokota T., Ogata M., Shigeta S. A mutant strain of varicella-zoster virus deficient in thymidine kinase-inducing activity. Fukushima J Med Sci. 1983 Jul;29(3-4):101–111. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES